Phase 2 UNITY-NHL Study Regarding Umbralisib

from Rare Discussions Hosted by CheckRare Editors

Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib. Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community. Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com. Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community. Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.

Episode details come from the podcast's RSS feed.

Embed this episode

Attribution link and audio player

Ready to play

Phase 2 UNITY-NHL Study Regarding Umbralisib

0:00 2:32

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Similar podcasts

Hanging With Headlock D! Darren Tompkins Step into the electrifying world of the Hanging With Headlock D Podcast, where FUN takes center stage! Join us for thrilling discussions with an array of guests diving into two of these awesome topics: Pro Wrestling, Food Adventures, Hot Sauce Explorations, and Fitness. 🎙️ Explicit

Frequently asked questions

How long is this episode of Rare Discussions?

This episode is 2 minutes long.

When was this Rare Discussions episode published?

This episode was published on April 15, 2021.

Can I download this Rare Discussions episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.